Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R. Saad F, et al. Among authors: diel ij. Ann Oncol. 2012 May;23(5):1341-1347. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10. Ann Oncol. 2012. PMID: 21986094 Free article.
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Stopeck AT, et al. Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Support Care Cancer. 2016. PMID: 26335402 Free PMC article. Clinical Trial.
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Stopeck AT, et al. Support Care Cancer. 2016 Jan;24(1):457-458. doi: 10.1007/s00520-015-2985-1. Support Care Cancer. 2016. PMID: 26482379 Free PMC article. No abstract available.
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. Martin M, et al. Clin Cancer Res. 2012 Sep 1;18(17):4841-9. doi: 10.1158/1078-0432.CCR-11-3310. Epub 2012 Aug 14. Clin Cancer Res. 2012. PMID: 22893628 Clinical Trial.
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Hadji P, et al. Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681681 Free article. Review.
Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Diel IJ, et al. Crit Rev Oncol Hematol. 2007 Dec;64(3):198-207. doi: 10.1016/j.critrevonc.2007.07.005. Epub 2007 Sep 12. Crit Rev Oncol Hematol. 2007. PMID: 17855108 Review.
Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.
Schneeweiss A, Diel I, Hensel M, Kaul S, Sinn HP, Unnebrink K, Rudlowski C, Lauschner I, Schuetz F, Egerer G, Haas R, Ho AD, Bastert G. Schneeweiss A, et al. Ann Oncol. 2004 Nov;15(11):1627-32. doi: 10.1093/annonc/mdh433. Ann Oncol. 2004. PMID: 15520063 Free article.
122 results